Ranitidine: A Proposed Mechanistic Rationale for NDMA Formation and a Potential Control Strategy.
1PhaRxmon Consulting, LLC, United States.
Journal of Pharmaceutical Sciences
|November 17, 2022
Summary
N-nitrosodimethylamine (NDMA) formation in ranitidine is explained by a new mechanism involving ranitidine autoxidation. Oxygen scavenging packaging may prevent NDMA by stopping nitrite release, stabilizing ranitidine drug products.
Area of Science:
- Pharmaceutical Chemistry
- Drug Stability
- Analytical Chemistry
Background:
- N-nitrosodimethylamine (NDMA) contamination in ranitidine hydrochloride has raised significant safety concerns.
- Previous studies have investigated NDMA formation in ranitidine drug substance (DS) solids, but a clear mechanism remained elusive.
- Ranitidine's unique vinyl nitro moiety is implicated in its instability.
Purpose of the Study:
- To elucidate the mechanistic pathway of N-nitrosodimethylamine (NDMA) formation in ranitidine.
- To identify key chemical processes leading to NDMA generation.
- To propose a practical strategy for stabilizing ranitidine against NDMA formation.
Main Methods:
- Proposed a mechanistic model for NDMA formation.
- Detailed the role of ranitidine autoxidation in releasing precursor molecules.
- Identified nitrosyl chloride (NOCl) as the nitrosating agent.
- Suggested the use of oxygen scavenging packaging systems.
Main Results:
- Autoxidation of ranitidine liberates nitrite ions and dimethylamine.
- Nitrite ions are converted to nitrosyl chloride (NOCl), a potent nitrosating agent.
- NDMA formation is directly linked to the release of nitrite ions from ranitidine.
Conclusions:
- A novel mechanism explains NDMA formation via ranitidine autoxidation and subsequent nitrosation.
- Oxygen scavenging packaging can inhibit ranitidine autoxidation, thereby preventing nitrite release.
- This approach offers a practical method to stabilize ranitidine drug substance and formulations against NDMA contamination.
More Related Videos
Related Concept Videos
Peptic Ulcer Disease IV: Management
128
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
128
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
553
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
553
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
623
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
623
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
505
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
505
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
563
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
563
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
485
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
485


